# Identification of Enhanced Cyclooxygenase-2 (COX-2) Inhibitors Beyond Curcumin Through Virtual Screening to Target Inflammation-Related Metabolic Complications

**Authors:** Marakiya T. Moetlediwa, Rudzani Ramashia, Mpatla B. Mangale, Carmen Pheiffer, Babalwa U. Jack, Elliasu Y. Salifu, Pritika Ramharack

PMC · DOI: 10.3390/ijms27041624 · International Journal of Molecular Sciences · 2026-02-07

## TL;DR

Researchers identified new COX-2 inhibitors through virtual screening, aiming to improve upon curcumin's limitations for treating inflammation-related diseases.

## Contribution

A novel set of COX-2 inhibitors with better drug-like properties than curcumin was identified using virtual screening and molecular modeling.

## Key findings

- 237 candidate compounds were identified from ZINC-22 database screening.
- Molecular docking prioritized 10 compounds with high binding affinities to COX-2.
- ZINC32605424 showed strongest COX-2 binding, stabilized by Van der Waals forces.

## Abstract

Cyclooxygenase-2 (COX-2) is a key enzyme in inflammatory pathways and serves as a therapeutic target in the treatment of inflammation-related diseases. Curcumin, a bioactive polyphenol from turmeric, has gained scientific attention due to its potent anti-inflammatory properties, largely mediated through COX-2 inhibition. However, the poor solubility and limited bioavailability of Curcumin limit its potential as a therapeutic agent targeting inflammatory diseases. We used an in silico approach to identify Curcumin-like scaffolds as novel COX-2 inhibitors with improved drug-like properties and therapeutic potential. A pharmacophore model derived from the key binding moieties of Curcumin was used to virtually screen the ZINC-22 database, identifying 237 candidate compounds for further evaluation. Molecular docking further prioritized these compounds to 10 candidates with the highest binding affinities. Most hits obeyed Lipinski’s rules, except for ZINC32605424 and ZINC47133707, which exhibited high LogP and molecular weight, respectively. Toxicity screening indicated that ZINC47133693 and ZINC09499196 exhibited high safety profiles, with ZINC15942488 being highly toxic. Furthermore, certain hits such as ZINC32605424 and ZINC15942488 were predicted to be P-glycoprotein substrates and potential inhibitors of cytochrome P450. Molecular dynamics simulations confirmed the stability of COX-2–ligand complexes, with critical interactions observed at conserved residues Tyr323 and Leu320. Binding energy calculations identified ZINC32605424 as the strongest COX-2 binder, mainly stabilized by Van der Waals forces. Overall, compounds such as ZINC32605424, ZINC08644750, ZINC47133693, and ZINC09499196 demonstrated potent COX-2 inhibition. These candidates show strong potential for further preclinical validation in studies investigating inflammation-related metabolic complications.

## Linked entities

- **Proteins:** COX2 (cytochrome c oxidase subunit II), Mdr65 (Multi drug resistance 65), CYP71B9 (cytochrome P450, family 71, subfamily B, polypeptide 9)
- **Chemicals:** Curcumin (PubChem CID 969516)

## Full-text entities

- **Genes:** CYP2C9 (cytochrome P450 family 2 subfamily C member 9) [NCBI Gene 1559] {aka CPC9, CYP2C, CYP2C10, CYPIIC9, P450-2C9, P450IIC9}, COX1 (cytochrome c oxidase subunit I) [NCBI Gene 4512] {aka COI, MTCO1}, CYP3A4 (cytochrome P450 family 3 subfamily A member 4) [NCBI Gene 1576] {aka CP33, CP34, CYP3A, CYP3A3, CYPIIIA3, CYPIIIA4}, AOPEP (aminopeptidase O (putative)) [NCBI Gene 84909] {aka AP-O, APO, C90RF3, C9orf3, DYT31, ONPEP}, CYP1A2 (cytochrome P450 family 1 subfamily A member 2) [NCBI Gene 1544] {aka CP12, CYPIA2, P3-450, P450(PA)}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, CYP4F3 (cytochrome P450 family 4 subfamily F member 3) [NCBI Gene 4051] {aka CPF3, CYP4F, CYPIVF3, LTB4H}, CYP2D6 (cytochrome P450 family 2 subfamily D member 6 (gene/pseudogene)) [NCBI Gene 1565] {aka CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2}, PPIG (peptidylprolyl isomerase G) [NCBI Gene 9360] {aka CARS-Cyp, CYP, SCAF10, SRCyp}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513] {aka COII, MTCO2}
- **Diseases:** renal impairment (MESH:D007674), hypersensitivity (MESH:D004342), liver toxicity (MESH:D056486), long-term inflammation (MESH:D000088562), Metabolic Complications (MESH:D020739), Carcinogenicity (MESH:D011230), tumorigenic (MESH:D002471), gastrointestinal complications (MESH:D005767), cardiovascular diseases (MESH:D002318), infection (MESH:D007239), insulin resistance (MESH:D007333), ulcer (MESH:D014456), Cytotoxicity (MESH:D064420), obesity (MESH:D009765), autoimmune disorders (MESH:D001327), acute toxicity (MESH:D000208), metabolic (MESH:D008659), fibrosis (MESH:D005355), Inflammation (MESH:D007249), injury to (MESH:D014947), bone fracture (MESH:D050723), pain (MESH:D010146), cancer (MESH:D009369), diabetes (MESH:D003920), swelling (MESH:D004487)
- **Chemicals:** polyphenol (MESH:D059808), lipid (MESH:D008055), Hydrogen (MESH:D006859), warfarin (MESH:D014859), Naproxen (MESH:D009288), Curcumin (MESH:D003474), ZINC26976295 (-), Na+ (MESH:D012964), ritonavir (MESH:D019438), Dexamethasone (MESH:D003907), octanol (MESH:D000442), water (MESH:D014867), Aspirin (MESH:D001241), arachidonic acid (MESH:D016718), Sulindac (MESH:D013467), Ibuprofen (MESH:D007052), ZINC (MESH:D015032), Prostaglandin (MESH:D011453), ketoconazole (MESH:D007654)
- **Species:** Curcuma longa (turmeric, species) [taxon 136217], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12940843/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12940843/full.md

## References

101 references — full list in the complete paper: https://tomesphere.com/paper/PMC12940843/full.md

---
Source: https://tomesphere.com/paper/PMC12940843